Advancing antisolvent membrane crystallisation

Reverse anti-solvent membrane crystallisation can produce the submicron sized drug particles required for long-acting injectable formulations through the unparalleled control of solvent mixing that is both precise and scalable. This disruptive technology mitigates the solid-state changes and particle size variability associated with historic drug production approaches to catalyse the development and manufacture of long-acting injectable medicines that are critically important to a wide range of treatments. The PhD candidate will work closely with the industrial sponsor (GlaxoSmithKline, GSK) and academic partners to develop this technology, including secondment into GSK, which may include on-site testing of the developed membrane crystallisation process at GSKs campus